A5052184331- Urticaria and Related Conditions
- Dermatology and Skin Diseases
- Peripheral Neuropathies and Disorders
- Immunotherapy and Immune Responses
- Multiple Sclerosis Research Studies
- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
Novartis (United Kingdom)
2022-2024
GW Pharmaceuticals (United Kingdom)
2022
Abstract Background Skin diseases can have a significant impact on the physical, psychological and social well‐being of patients. Quantification burden chronic spontaneous urticaria (CSU) compared to other dermatological conditions is limited. Objectives To evaluate comparative humanistic economic CSU, atopic dermatitis (AD), psoriasis (PSO) in five European countries (EU5). Methods This cross‐sectional analysis data from adult respondents with physician diagnosis AD PSO 2020 National Health...
Several disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis (RRMS) reduce relapse rates and slow disease progression. RRMS DMTs have varying efficacy administration routes; prescribed first may not be the most effective on relapses or Here, we aimed to quantify benefit of initiating ofatumumab, a high-efficacy DMT, earlier in treatment pathway.Aggregate data from real-world cohort patients with RRMS, who were eligible dimethyl fumarate (DMF) ofatumumab within UK...